Table 2.

Clinical trials on drug combinations and breaking down resistance to immunotherapy.

Clinical Trial ID	Primary Endpoint	Treatment
NCT04782622	ORR and PFS	apatinib + camrelizumab
NCT04691388	PFS	Anlotinib + sinidilizumab
NCT04670107	PFS and OS AE (adverse event caused by the combination)	anlotinib in combination with immune checkpoint inhibitors
NCT03833440	The 12-week disease control rate	Arm A: durvalumab + monalizumab (IPH2201), Arm B: durvalumab + oleclumab (MEDI9447), Arm C: durvalumab + ceralasertib (AZD6738), Arm D: standard of third or fourth-line chemotherapy (docetaxel)
NCT03262779	ORR	nivolumab + ipilimumab
NCT03600701	ORR	atezolizumab + cobimetinib
NCT03841110	Maximum tolerated dose	FT500 + cyclophosphamide + fludarabine FT500 + nivolumab + cyclophosphamide + fludarabine FT500 + pembrolizumab + cyclophosphamide + fludarabine FT500 + atezolizumab + cyclophosphamide + fludarabine FT500 + IL-2 (proleukin, aldesleukin) + nivolumab + cyclophosphamide + fludarabine FT500 + IL-2 (proleukin, aldesleukin) + pembrolizumab + cyclophosphamide + fludarabine FT500 + IL-2 (proleukin, aldesleukin) + atezolizumab + cyclophosphamide + fludarabine